PTGX FY 2017 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M

Gross Profit

$20M100.0% margin

Operating Income

-$38M-188.9% margin

Net Income

-$37M-184.2% margin

EPS (Diluted)

$-2.09

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$3M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$164M

Total Liabilities

$43M

Stockholders' Equity

-$102M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$0	—
Gross Profit	$20M	-$317,000	+6429.0%
Operating Income	-$38M	-$33M	-16.0%
Net Income	-$37M	-$37M	+0.6%